Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis (NCT06517875)
A Phase 2 Open-label Study to Evaluate Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Primary or Secondary Myelofibrosis
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this Phase 2 study is to evaluate the efficacy and safety of momelotinib (MMB) in combination with luspatercept (LUSPA) in participants with transfusion dependence (TD) primary myelofibrosis (PMF) or Post-polycythemia vera (PV)/ essential thrombocythemia (ET) myelofibrosis (MF) who are either janus kinase (JAK) inhibitor (JAKi) naïve or experienced.
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — Ann Arbor, Michigan
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (33 Sites)
Showing the first 25 of 33 sites.
- GSK Investigational Site — Ann Arbor, Michigan
- GSK Investigational Site — New York, New York
- GSK Investigational Site — Nashville, Tennessee
- GSK Investigational Site — Houston, Texas
- GSK Investigational Site — Seattle, Washington
- GSK Investigational Site — Vancouver, British Columbia
- GSK Investigational Site — Toronto, Ontario
- GSK Investigational Site — Montreal, Quebec
- GSK Investigational Site — Montreal, Quebec
- GSK Investigational Site — Angers,
- GSK Investigational Site — Brest,
- GSK Investigational Site — Lyon,
- GSK Investigational Site — Nice,
- GSK Investigational Site — Nîmes,
- GSK Investigational Site — Paris,
- GSK Investigational Site — Poitiers,
- GSK Investigational Site — Essen,
- GSK Investigational Site — Jena,
- GSK Investigational Site — Lübeck,
- GSK Investigational Site — Mannheim,
- GSK Investigational Site — Bologna,
- GSK Investigational Site — Catania,
- GSK Investigational Site — Florence,
- GSK Investigational Site — Meldola FC,
- GSK Investigational Site — Milan,
📞 Contact the Study Coordinator
Phone: (877) 379-3718
Email: GSKClinicalSupportHD@gsk.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Primary Myelofibrosis
- CINC424A2X01B Rollover Protocol — Darlinghurst, New South Wales
- P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk — Los Angeles, California
- Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis — Seattle, Washington
- Study of Canakinumab in Patients With Myelofibrosis — Los Angeles, California
- Decitabine in Treating Patients With Myelofibrosis — Chicago, Illinois
- A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis — Birmingham, Alabama
Explore by condition: All Primary Myelofibrosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.